

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer (including review of TA212) [ID6465]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
None identified
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/A
3. Has any change to the draft scope been agreed to highlight potential equality issues?
N/A
4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
N/A

**Approved by Associate Director (name):** .....Janet Robertson.....

**Date:** 02 April 2025